Bronchus anastomosis healing depending on type of neoadjuvant therapy

ConclusionsNeoadjuvant radiotherapy is associated with a worse wound healing of the anastomosis after sleeve lobectomy in lung cancer. There seems to be a higher risk of anastomotic insufficiency and complications.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

SummaryAssociations between treatment outcomes of immune checkpoint inhibitors and metastatic sites in advanced non-small cell lung cancer (NSCLC) are not well known. Therefore, this multicenter retrospective study aimed to investigate the predictive factors of metastatic sites after first-line pembrolizumab treatment for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. We retrospectively analyzed advanced NSCLC patients with a PD-L1 TPS ≥50% who underwent first-line pembrolizumab therapy at 11 institutions between February 2017 and April 2018. Clinical data collected from medical records included metas...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
LORBRENA is a drug used to treat patients with a type of non-small cell lung cancer.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
ConclusionsAmong NSCLC patients in an equal access health system, the likelihood of late stage at diagnosis differed by specific comorbid diseases.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Zhiguang Yang, Xingyu Lin, Peng Zhang, Yunpeng Liu, Zihao Liu, Benxin Qian, Xing Liu, Guoguang ShaoAbstractLong non-coding RNA LINC00525 has been reported to be upregulated in non-small cell lung cancer (NSCLC), however, its biological roles and underlying mechanism involved in modulation of NSCLC remain largely unclear. Real-time PCR were performed to determine the expression of LINC00525 and miR-338-3p in NSCLC tissues and cell lines. Cell proliferation was detected by Cell Counting Kit-8 (CCK-8) and colony-formation assays. Cell m...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conclusions. Today biological specimens donated by 343 registrants with lung cancer are available at the RHTR. Among them, 255 donors (74%) are Mayak PA workers hired at the main facilities (reactors, plutonium production and radiochemical plants) in 1948-1982. These workers donated about 6024 specimens of lung tissues (tumor and tumor-free) stored mostly as formalin-fixed paraffin-embedded tissue blocks (31%) and histology slides (64%); in addition they donated 1800 specimens of blood/blood components, buccal epithelium cells and sputum. Among histologic types identified for these lung cancer cases, adenocarcinoma and sma...
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
Polyphyllin VII induces apoptotic cell death via inhibition of the PI3K/Akt and NF‑κB pathways in A549 human lung cancer cells. Mol Med Rep. 2020 Feb;21(2):597-606 Authors: He H, Xu C, Zheng L, Wang K, Jin M, Sun Y, Yue Z Abstract Polyphyllin VII is an active compound isolated from Paris polyphylla, which is termed Chonglou in China. The present study was designed to investigate the underlying mechanisms of the antitumor effect of Polyphyllin VII in lung cancer cells. The cytotoxic effect of Polyphyllin VII in human lung cancer A549 cells was analyzed; the results revealed an IC50 value of 0.41...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 25 January 2020Source: The Annals of Thoracic SurgeryAuthor(s): Driss Raissi, Qian Yu, Victor A. Ferraris, Michael WinklerAbstractEndobronchial stenting is a well-established palliative approach in lung cancer patients with airway obstruction secondary to tumor burden. However, endobronchial stenting can be complicated by stent erosion into adjacent vessels. While most cases of endobronchial stent related hemoptysis can be treated by stent revision and/or surgical resection, here, we present a case managed by endovascular pulmonary arterial stent placement as a last resort option in the m...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Conclusions: The results reveal high discriminant power of chromosomes 8, 5, 1, 3, and 19 for identifying cancer with the highest sensitivity of 75% yielded by chromosome 5. Bottom 5 chromosomes 9, 6, 4, 13, and 21 show low discriminant power with accuracy of below 54% where true cancer and normal samples are grouped into substantially overlapping groups using copy numbers. This indicates the similarities of copy numbers obtained for cancer and normal samples on these chromosomes. PMID: 31977287 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
More News: Bronchoscopy | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Databases & Libraries | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study